Literature DB >> 26208998

Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Wenjia Chen1, Jamie Thomas2, Mohsen Sadatsafavi3, J Mark FitzGerald4.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory disorder associated with increased comorbid prevalence of cardiovascular diseases. We aimed to quantify the magnitudes of association between overall and specific types of cardiovascular disease, major cardiovascular risk factors, and COPD.
METHODS: We searched Cochrane, Medline, and Embase databases for studies published between Jan 1, 1980, and April 30, 2015, on the prevalence of cardiovascular disease and its risk factors in patients with COPD versus matched controls or random samples from the general public. We assessed associations with random-effects meta-analyses. We studied heterogeneity and biases with random-effects meta-regressions, jackknife sensitivity analyses, assessment of funnel plots, and Egger tests.
FINDINGS: We identified 18,176 unique references and included 29 datasets in the meta-analyses. Compared with the non-COPD population, patients with COPD were more likely to be diagnosed with cardiovascular disease (odds ratio [OR] 2·46; 95% CI 2·02-3·00; p<0·0001), including a two to five times higher risk of ischaemic heart disease, cardiac dysrhythmia, heart failure, diseases of the pulmonary circulation, and diseases of the arteries. Additionally, patients with COPD reported hypertension more often (OR 1·33, 95% CI 1·13-1·56; p=0·0007), diabetes (1·36, 1·21-1·53; p<0·0001], and ever smoking (4·25, 3·23-5·60; p<0·0001). The associations between COPD and these cardiovascular disease types and cardiovascular disease risk factors were consistent and valid across studies. Enrolment period, age, quality of data, and COPD diagnosis partly explained the heterogeneity.
INTERPRETATION: The coexistence of COPD, cardiovascular disease, and major risk factors for cardiovascular disease highlights the crucial need for the development of strategies to screen for and reduce cardiovascular risks associated with COPD. FUNDING: Canadian Institutes of Health Research.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26208998     DOI: 10.1016/S2213-2600(15)00241-6

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  134 in total

1.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.

Authors:  Wassim W Labaki; Meng Xia; Susan Murray; Jeffrey L Curtis; R Graham Barr; Surya P Bhatt; Eugene R Bleecker; Nadia N Hansel; Christopher B Cooper; Mark T Dransfield; J Michael Wells; Eric A Hoffman; Richard E Kanner; Robert Paine; Victor E Ortega; Stephen P Peters; Jerry A Krishnan; Russell P Bowler; David J Couper; Prescott G Woodruff; Fernando J Martinez; Carlos H Martinez; MeiLan K Han
Journal:  Respir Med       Date:  2018-06-05       Impact factor: 3.415

Review 2.  The Role of Chest Computed Tomography in the Evaluation and Management of the Patient with Chronic Obstructive Pulmonary Disease.

Authors:  Wassim W Labaki; Carlos H Martinez; Fernando J Martinez; Craig J Galbán; Brian D Ross; George R Washko; R Graham Barr; Elizabeth A Regan; Harvey O Coxson; Eric A Hoffman; John D Newell; Douglas Curran-Everett; James C Hogg; James D Crapo; David A Lynch; Ella A Kazerooni; MeiLan K Han
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

3.  A Multidimensional Risk Score to Predict All-Cause Hospitalization in Community-Dwelling Older Individuals With Obstructive Lung Disease.

Authors:  Rosanne J H C G Beijers; Bram van den Borst; Anne B Newman; Sachin Yende; Stephen B Kritchevsky; Patricia A Cassano; Douglas C Bauer; Tamara B Harris; Annemie M W J Schols
Journal:  J Am Med Dir Assoc       Date:  2016-02-23       Impact factor: 4.669

Review 4.  Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.

Authors:  Mario Cazzola; Luigino Calzetta; Barbara Rinaldi; Clive Page; Giuseppe Rosano; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPD.

Authors:  Tadahiro Goto; Yuichi J Shimada; Mohammad Kamal Faridi; Carlos A Camargo; Kohei Hasegawa
Journal:  J Gen Intern Med       Date:  2018-06-08       Impact factor: 5.128

6.  Hidden in Plain Sight: Lung Impairment in Ischemic Heart Disease.

Authors:  Surya P Bhatt
Journal:  Am J Respir Crit Care Med       Date:  2016-09-01       Impact factor: 21.405

7.  Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.

Authors:  Meng-Ting Wang; Jun-Ting Liou; Chen Wei Lin; Chen-Liang Tsai; Yun-Han Wang; Yu-Juei Hsu; Jyun-Heng Lai
Journal:  JAMA Intern Med       Date:  2018-02-01       Impact factor: 21.873

8.  Metoprolol for the Prevention of Acute Exacerbations of COPD.

Authors:  Mark T Dransfield; Helen Voelker; Surya P Bhatt; Keith Brenner; Richard Casaburi; Carolyn E Come; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Umur Hatipoğlu; Erika S Helgeson; Vipul V Jain; Ravi Kalhan; David Kaminsky; Robert Kaner; Ken M Kunisaki; Allison A Lambert; Matthew R Lammi; Sarah Lindberg; Barry J Make; Fernando J Martinez; Charlene McEvoy; Ralph J Panos; Robert M Reed; Paul D Scanlon; Frank C Sciurba; Anthony Smith; Peruvemba S Sriram; William W Stringer; Jeremy A Weingarten; J Michael Wells; Elizabeth Westfall; Stephen C Lazarus; John E Connett
Journal:  N Engl J Med       Date:  2019-10-20       Impact factor: 91.245

Review 9.  Cardiovascular risk, chronic obstructive pulmonary disease and pulmonary rehabilitation: Can we learn from cardiac rehabilitation?

Authors:  Filip Jj Triest; Sally J Singh; Lowie Egw Vanfleteren
Journal:  Chron Respir Dis       Date:  2016-04-14       Impact factor: 2.444

10.  Chronic obstructive pulmonary disease is not a risk factor for polyneuropathy: A prospective controlled study.

Authors:  Nora A Visser; Nicolette C Notermans; Ferdinand Teding van Berkhout; Leonard H van den Berg; Alexander Fje Vrancken
Journal:  Chron Respir Dis       Date:  2016-03-15       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.